TY - JOUR
T1 - Microphysiological systems and low-cost microfluidic platform with analytics
AU - Smith, Alec S.
AU - Long, Christopher J.
AU - Berry, Bonnie J.
AU - McAleer, Christopher
AU - Stancescu, Maria
AU - Molnar, Peter
AU - Miller, Paula G.
AU - Esch, Mandy B.
AU - Prot, Jean Matthieu
AU - Hickman, James J.
AU - Shuler, Michael L.
N1 - Funding Information:
This research was funded by National Institutes of Health grant numbers 1UH2TR000516-01, R01NS050452 and R01EB005459. The publication costs for this article were funded by National Institutes of Health grant number UH2TR000516.
PY - 2013/12/20
Y1 - 2013/12/20
N2 - A multiorgan, functional, human in vitro assay system or 'Body-on-a-Chip' would be of tremendous benefit to the drug discovery and toxicology industries, as well as providing a more biologically accurate model for the study of disease as well as applied and basic biological research. Here, we describe the advances our team has made towards this goal, as well as the most pertinent issues facing further development of these systems. Description is given of individual organ models with appropriate cellular functionality, and our efforts to produce human iterations of each using primary and stem cell sources for eventual incorporation into this system. Advancement of the 'Body-on-a-Chip' field is predicated on the availability of abundant sources of human cells, capable of full differentiation and maturation to adult phenotypes, for which researchers are largely dependent on stem cells. Although this level of maturation is not yet achievable in all cell types, the work of our group highlights the high level of functionality that can be achieved using current technology, for a wide variety of cell types. As availability of functional human cell types for in vitro culture increases, the potential to produce a multiorgan in vitro system capable of accurately reproducing acute and chronic human responses to chemical and pathological challenge in real time will also increase.
AB - A multiorgan, functional, human in vitro assay system or 'Body-on-a-Chip' would be of tremendous benefit to the drug discovery and toxicology industries, as well as providing a more biologically accurate model for the study of disease as well as applied and basic biological research. Here, we describe the advances our team has made towards this goal, as well as the most pertinent issues facing further development of these systems. Description is given of individual organ models with appropriate cellular functionality, and our efforts to produce human iterations of each using primary and stem cell sources for eventual incorporation into this system. Advancement of the 'Body-on-a-Chip' field is predicated on the availability of abundant sources of human cells, capable of full differentiation and maturation to adult phenotypes, for which researchers are largely dependent on stem cells. Although this level of maturation is not yet achievable in all cell types, the work of our group highlights the high level of functionality that can be achieved using current technology, for a wide variety of cell types. As availability of functional human cell types for in vitro culture increases, the potential to produce a multiorgan in vitro system capable of accurately reproducing acute and chronic human responses to chemical and pathological challenge in real time will also increase.
UR - http://www.scopus.com/inward/record.url?scp=84891351288&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84891351288&partnerID=8YFLogxK
U2 - 10.1186/scrt370
DO - 10.1186/scrt370
M3 - Review article
C2 - 24565109
AN - SCOPUS:84891351288
SN - 1757-6512
VL - 4
JO - Stem Cell Research and Therapy
JF - Stem Cell Research and Therapy
IS - SUPPL.1
M1 - S9
ER -